REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.

@article{Costa2017REOXEO,
  title={REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.},
  author={Talita Cassanta Costa and Jos{\'e} Francisco Dimas Nu{\~n}ez and Tiago Felismino and Leonardo Boente and Celso A Mello},
  journal={Clinical colorectal cancer},
  year={2017},
  volume={16 4},
  pages={
          316-323
        }
}
BACKGROUND Treatment of metastatic colorectal adenocarcinoma (mCRC) has evolved, and survival is over 30 months in contemporary trials. Nevertheless, there is a paucity of effective regimes after the first or second-line treatment. Thus, reexposure to previously used drugs has become a treatment strategy for some patients. We aimed to evaluate the efficacy… CONTINUE READING